Neurocrine Biosciences (NASDAQ:NBIX) Price Target Lowered to $163.00 at Guggenheim
Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its price objective reduced by Guggenheim from $165.00 to $163.00 in a report published on Monday,Benzinga reports. They currently have a buy rating on the stock. NBIX has been the subject of several other research reports. Royal Bank of Canada decreased their price target on Neurocrine Biosciences from […]
Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its price objective reduced by Guggenheim from $165.00 to $163.00 in a report published on Monday,Benzinga reports. They currently have a buy rating on the stock. NBIX has been the subject of several other research reports. Royal Bank of Canada decreased their price target on Neurocrine Biosciences from […]
